If you're a member: Log-in to get more information about this trial.
IBCSG 22-00
Low-dose cytotoxics as "anti-angiogenesis treatment" following adjuvant induction chemotherapy for patients with ER-negative and PgR-negative breast cancer
Biological Material / Translational Research
Serum Substudy
Assessment of Vascular Endothelial Growth Factor (VEGF), Soluble Her2 Protein (NRP, Neu-Related Protein), and Vascular Cellular Adhesion Molecule-1 (VCAM-1) in serum samples.
Results & Publications
- Specific publication list for Trial 22-00 (May 2026)
ETOP IBCSG Partners Foundation
Effingerstrasse 33
3008 Bern, Switzerland
Contact
Phone: +41 31 511 94 00
E-mail: contact@etop.ibcsg.org
Donating & Supporting